Azathioprine showed no clear difference in adverse events compared with infliximab (moderate certainty).
It is very uncertain whether 6‐Mercaptopurine changes adverse events compared with methotrexate (very low certainty).
It is very uncertain whether azathioprine changes any adverse events compared with placebo (very low certainty).
Azathioprine showed no clear difference in serious adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine changes serious adverse events compared with budesonide (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes serious adverse events compared with methotrexate (very low certainty).
Azathioprine showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine changes withdrawals due to adverse events compared with budesonide (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes withdrawals due to adverse events compared with methotrexate (very low certainty).
Azathioprine + infliximab showed no clear difference in adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine and infliximab changes adverse events compared with infliximab (very low certainty).
Azathioprine + infliximab probably leads to lower serious adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine and infliximab changes serious adverse events compared with infliximab (very low certainty).
Azathioprine + infliximab showed no clear difference in withdrawals due to adverse events compared with infliximab (moderate certainty).
It is very uncertain whether azathioprine and infliximab changes withdrawals due to adverse events compared with infliximab (very low certainty).